Squamous Cell Carcinoma of the Urinary Tract

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS research · 2026-04-24
Clinical Trial Update: Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... [Phase 2]
A Phase 2 clinical trial (SMART) is assessing sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors and is current…
CLINICAL_TRIALS trial_result · 2022-10-03
Clinical Trial Update: Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). [Phase 2]
Phase 2 clinical trial update for atezolizumab in immunotherapy-naive patients with urinary tract squamous cell carcinoma (UTSCC).